Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Kv7 modulators merit targeted development for neuropathic pain; leaves open clinical efficacy and safety in patients.
ADVERTISEMENT RETURN TO ISSUEPREVPerspectiveNEXTKv7 (KCNQ) Channel Modulators and Neuropathic PainGordon Munro and William Dalby-BrownView Author Information NeuroSearch A/S, Pederstrupvej 93, DK-2750 Ballerup, Denmark Cite this: J. Med. Chem. 2007, 50, 11, 2576–2582Publication Date (Web):May 10, 2007Publication History Received16 August 2006Published online10 May 2007Published inissue 1 May 2007https://doi.org/10.1021/jm060989lCopyright © 2007 American Chemical SocietyRIGHTS & PERMISSIONSArticle Views1793Altmetric-Citations47LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstract
No takes yet. Share an insight, caveat, or question.
Munro et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: